Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2024 · 10-Q
Revenue$1.10M$1.10M−39.0% vs Q3 2023 Net Income-$1.12M-$1.12MN/M vs Q3 2023 EPS Diluted-$0.65-$0.65N/M vs Q3 2023 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$46,952N/M Free Cash Flowderived-$37,732— Margins · derivedGross margin-47.2%−34.3 pt vs Q3 2023
Operating margin-98.6%−59.1 pt vs Q3 2023
Net margin-101.6%−58.5 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 13, 2024 · 44 d after period end